Radius Health Inc logo

RDUS - Radius Health Inc News Story

$13.46 -0.3  -2.5%

Last Trade - 9:00pm

Mid Cap
Market Cap £491.7m
Enterprise Value £559.6m
Revenue £153.7m
Position in Universe 2679th / 6406

Radius Health Divests RAD 140 Program to Ellipses Pharma

Thu 1st October, 2020 1:45pm
For best results when printing this announcement, please click on link below:

* Business development step enables molecule to move forward
* Program progression will be at no financial risk to Radius
* Reinforces Radius’ focus on execution of core business
WALTHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:
RDUS) announced today that the company has successfully sold its second
oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing
Radius’s divestment of its oncology assets. Under the agreement, Ellipses
Pharma will be responsible for the clinical development and commercialization
of the asset. Radius will be entitled to receive royalties on the program as
it advances with Ellipses.

RAD140 is a non-steroidal selective androgen receptor (AR) modulator (SARM).
In a Phase 1a study of RAD140 in 22 heavily pre-treated postmenopausal women
with ER+/HER2- locally advanced or metastatic breast cancer, the compound was
well tolerated, showed evidence of clinical activity and target engagement of
the AR.

Dr Rajan Jethwa, Chief Executive Officer of Ellipses Pharma, commented: “We
are pleased to be able to progress this project and results to date have been
encouraging. We look forward to taking this molecule into more advanced trials
at the earliest opportunity.”

About Ellipses Pharma
Ellipses Pharma is an international drug development company, focused
exclusively on the devlopment of innovative cancer medicines and treatments.
Headquartered in London, Ellipses is run by a world class leadership team,
leveraging the expertise of the world’s largest cancer-focused key opinion
leader group to oversee a rapidly growing pipeline of high quality clinical
oncology opportunities. Its worldwide reach and asset-focused approach
transforms the clinical trials’ process to make the very best drugs and
therapies available to patients with cancer at unprecedented speed. For more
information, please visit https://ellipses.life/

About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is
committed to developing and commercializing innovative endocrine therapeutics.
Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the
U.S. Food and Drug Administration for the treatment of postmenopausal women
with osteoporosis at high risk for fracture. The Radius clinical pipeline
includes the investigational use of abaloparatide injection for the treatment
of men with osteoporosis, an investigational abaloparatide-patch for potential
use in osteoporosis and the investigational drug elacestrant (RAD1901) for
potential use in hormone-receptor positive breast cancer out-licensed to
Menarini Group. For more information, please visit www.radiuspharm.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.  All statements
contained in this press release that do not relate to matters of historical
fact should be considered forward-looking statements.

These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including, but not
limited to, the following: risks related to RAD140’s clinical development
and, if approved, commercialization, including the impact of the COVID-19
pandemic thereon. These and other important risks and uncertainties discussed
in our filings with the Securities and Exchange Commission, or SEC, including
under the caption "Risk Factors" in our Annual Report on Form 10-K for the
year ending December 31, 2019 and subsequent filings with the SEC, could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release.

Radius Investor Relations & Media Contact:
Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011

Ellipses Pharma Investor Relations & Media Contact:
Ramsay Smith, Executive Director Media House International Ltd.
Email: ramsay@mediahouse.co.uk
Phone +44 7788 414856


GlobeNewswire, Inc. 2020
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.